Adjuvant Therapy in Patients With Resected Poor-Risk Head and Neck Cancer
- 10 June 2006
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (17), 2629-2635
- https://doi.org/10.1200/jco.2005.05.0906
Abstract
In patients with locally or regionally advanced head and neck carcinomas, postoperative radiotherapy has historically been the adjuvant therapy applied for patients with prognostically worrisome pathologic features. Any improvement in therapeutic index achieved by adding cytotoxic agents to postoperative radiotherapy remained controversial. However, two recent randomized trials, conducted in parallel in Europe and the United States, produced level I evidence regarding improved efficacy in this setting for the concurrent administration of chemotherapy and radiotherapy. High-dose cisplatin and irradiation can now be considered the standard therapeutic approach for resected poor-risk disease. The presence of positive margins and/or nodal extracapsular spread in the surgical specimens are the subgroups that appear to benefit in the most significant way from the addition of chemotherapy to radiation. Many questions regarding the optimization of adjuvant treatments still remain unanswered, especially with respect to improvement of patient compliance, integration of novel drugs targeting both locoregional and systemic control, and modulation of treatment intensity according to risk levels.Keywords
This publication has 46 references indexed in Scilit:
- Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)Head & Neck, 2005
- Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: The importance of the overall treatment timeInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neckHead & Neck, 2002
- Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancerInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Precisely defining high-risk operable head and neck tumors based on rtog #85-03 and #88-24: Targets for postoperative radiochemotherapy?Head & Neck, 1998
- Combined modality treatment with radiotherapy and chemotherapyRadiotherapy and Oncology, 1989
- Combined radiation therapy and surgery in the management of advanced head and neck cancer: Final report of study 73–03 of the radiation therapy oncology groupHead & Neck Surgery, 1987
- Failure at the primary site following multimodality treatment in advanced head and neck cancerHead & Neck Surgery, 1984
- Prognostic factors of neck node metastasisClinical Otolaryngology, 1982
- Radiotherapeutic Management of Surgical Recurrences and Postoperative Residuals in Tumors ofthe Head and NeckRadiology, 1970